公开(公告)号：US20250107771A1

公开(公告)日：2025-04-03

申请号：US18834815

申请日：2022-11-24

Applicant: Hidetsugu ASANOI ,  HEARTLAB, INC.

Inventor： Hidetsugu ASANOI

IPC: A61B7/04 ,  A61B5/00

Abstract: A heart sound analysis device 3 that analyzes a heart sound signal acquired from a subject comprises an amplitude variation waveform generation unit 33a that generates an amplitude variation waveform of the heart sound signal; a peak detection unit 33b that detects maximum peaks in the amplitude variation waveform; a time interval calculation unit 33c that calculates time intervals between the maximum peaks; and a prediction support unit 33d that supports the prediction of the state of the subject based on the time intervals.

公开(公告)号：US11061039B2

公开(公告)日：2021-07-13

申请号：US16208739

申请日：2018-12-04

Applicant: CLEVELAND HEARTLAB, INC.

Inventor： Timothy Collier ,  Cory Bystrom ,  Angela Higgins

IPC: G01N33/483 ,  G01N33/92 ,  G01N1/34 ,  C07K14/775

Abstract: The present invention provides methods, kits, and compositions for purifying HDL molecules from a sample (e.g., blood sample) using HDL tagging molecules comprising an HDL lipophilic core binding peptide (e.g., portion of ApoA1) and an affinity tag. The present invention also provides methods, kits, and compositions for detecting non-fragmented ApoA1 with mass spectrometry. The present invention further provides methods, kits, and compositions for tagging HDL molecules in a sample with detectably labeled ApoA1 molecules such that the ratio of detectably labeled ApoA1 molecules to native ApoA1 proteins may be determined.

公开(公告)号：US10921331B2

公开(公告)日：2021-02-16

申请号：US15656592

申请日：2017-07-21

Applicant: Cleveland HeartLab, Inc.

Inventor： Cory Bystrom ,  Timothy Collier

IPC: G01N33/92

Abstract: Provided herein are methods, systems, and compositions for detecting one or more HDL-associated proteins (e.g., ApoC3; ApoC3 and ApoA1; ApoC3 and SAA1/2; or proteins in Biomarker Panels 1-30) in a sample from a subject with, or suspected of having, cardiovascular disease (CVD) or other HDL related disease. In certain embodiments, such methods, systems, and compositions are used to determine the approximate risk of CVD (or other disease) for a subject, and/or the approximate cholesterol efflux capacity (CEC) of a sample.

公开(公告)号：US10466260B2

公开(公告)日：2019-11-05

申请号：US15788876

申请日：2017-10-20

Applicant: Cleveland HeartLab, Inc.

Inventor： Cory Bystrom ,  Timothy Collier

IPC: A61K38/00 ,  G01N33/92

Abstract: Provided herein are compositions, systems, and methods for extracting and detecting at least one HDL-associated protein (e.g., ApoA1) from a sample (e.g., plasma or serum sample). In certain embodiments, a strong organic acid and hydrophilic organic solvent are mixed with the sample; after centrifugation, the supernatant is transferred to a second container where it is mixed with a non-polar organic solvent; after centrifugation, the lower aqueous layer is transferred to a third container; and then at least a portion of the transferred aqueous layer is subjected to a detection assay such that at least one HDL-associated protein is detected.

公开(公告)号：US20180031586A1

公开(公告)日：2018-02-01

申请号：US15788876

申请日：2017-10-20

Applicant: Cleveland HeartLab, Inc.

Inventor： Cory Bystrom ,  Timothy Collier

IPC: G01N33/92

CPC classification number: G01N33/92 ,  G01N2333/775

Abstract: Provided herein are compositions, systems, and methods for extracting and detecting at least one HDL-associated protein (e.g., ApoA1) from a sample (e.g., plasma or serum sample). In certain embodiments, a strong organic acid and hydrophilic organic solvent are mixed with the sample; after centrifugation, the supernatant is transferred to a second container where it is mixed with a non-polar organic solvent; after centrifugation, the lower aqueous layer is transferred to a third container; and then at least a portion of the transferred aqueous layer is subjected to a detection assay such that at least one HDL-associated protein is detected.

公开(公告)号：US20160084856A1

公开(公告)日：2016-03-24

申请号：US14858111

申请日：2015-09-18

Applicant: Cleveland HeartLab, Inc.

Inventor： Cory Bystrom ,  Timothy Collier

IPC: G01N33/92

CPC classification number: G01N33/92 ,  G01N2333/775

Abstract: Provided herein are compositions, systems, and methods for extracting and detecting at least one HDL-associated protein (e.g., ApoA1) from a sample (e.g., plasma or serum sample). In certain embodiments, a strong organic acid and hydrophilic organic solvent are mixed with the sample; after centrifugation, the supernatant is transferred to a second container where it is mixed with a non-polar organic solvent; after centrifugation, the lower aqueous layer is transferred to a third container; and then at least a portion of the transferred aqueous layer is subjected to a detection assay such that at least one HDL-associated protein is detected.

Abstract translation: 本文提供了用于从样品（例如血浆或血清样品）提取和检测至少一种HDL相关蛋白（例如ApoA1）的组合物，系统和方法。 在某些实施方案中，将强有机酸和亲水性有机溶剂与样品混合; 离心后，将上清转移到第二容器中，在其中与非极性有机溶剂混合; 离心后，将下层水层转移到第三容器中; 然后将至少一部分转移的水层进行检测测定，使得至少检测到一种HDL相关蛋白。

公开(公告)号：US20030235918A1

公开(公告)日：2003-12-25

申请号：US10412838

申请日：2003-04-12

Applicant: Berkeley HeartLab, Inc.

Inventor： David Shewmake ,  Frank Ruderman ,  Christopher Boggess ,  Faith Clendenen

IPC: G01N031/00

CPC classification number: G01N33/92 ,  C25B1/285 ,  G01N2800/32 ,  G01N2800/52 ,  Y10T436/104165

Abstract: The invention provides a data base of LDL, I, Ia, IIb, IIIa, IIb, IVa, IVb and HDL2a, HDL2b, HDL 3a, HDL 3b and HDL 3c together with patient data such as HDL-C, LDL-C, Apo A, ApoB, Lp(a) and patient personal data useful for treatment, diagnosing, and monitoring cardiovascular disease. The data base contains the LDL and HDL subfraction data in quantitative mg/dl values and permits deriving relationship amongst the LDL and HDL values and cardiovascular disease. Quantitative data permits more effective treatment and monitoring of cardiovascular disease. For example, quantitative differences in LDL and HDL subclass levels can determine the need for more or less aggressive treatment. The data base which includes patient events, procedures, interventions which is correlated to LDL and HD1 quantitative subclass data permits development of personalized patient treatment plans and monitoring the effectiveness of such treatment. Thus, LDL and HDL quantitative subfraction data can be used to more effectively treat and monitor cardiovascular disease. The invention, for example, provides a method for identifying patients with normal NCEP lipid levels who are in need of treatment for cardiovascular disease comprising measuring one or more LDL or HDL particle subclass levels and identifying abnormal LDL or HDL subclass levels. LDL III a & b and HDL 2b are preferred subclasses.

Abstract translation: 本发明提供LDL，I，Ia，IIb，IIIa，IIb，IVa，IVb和HDL2a，HDL2b，HDL 3a，HDL 3b和HDL 3c的数据库以及患者数据如HDL-C，LDL-C，Apo A，ApoB，Lp（a）和患者个人资料可用于治疗，诊断和监测心血管疾病。 数据库包含定量mg / dl值中的LDL和HDL次级分数据，并允许LDL和HDL值与心血管疾病之间的关系。 定量数据可以更有效地治疗和监测心血管疾病。 例如，LDL和HDL亚类水平的定量差异可以确定对或多或少积极治疗的需要。 包括与LDL和HD1定量亚类数据相关的患者事件，程序，干预措施的数据库允许开发个性化的患者治疗计划并监测此类治疗的有效性。 因此，LDL和HDL定量分数据可用于更有效地治疗和监测心血管疾病。 例如，本发明提供了一种用于鉴定需要治疗心血管疾病的正常NCEP脂质水平的患者的方法，包括测量一种或多种LDL或HDL颗粒亚类水平并鉴定异常的LDL或HDL亚类水平。 LDL III a＆b和HDL 2b是优选的亚类。